. 2023 Aug 15;13(4):156–163.

Table 1.

Patients’ characteristics and imaging protocol

Characteristics
Patients (n)	55
Age (years)	60.3 ± 12.4
Male:female	24:31
FDG injection dose	182 ± 36.5 MBq (range 110-269)
Mean glucose level	99.3 ± 11.4 mg/dl (range 82-142)
Scan time from FDG injection	PET/CT: 63 ± 8 min
Scan time from FDG injection	PET/MRI: 98 ± 14 min
Image reconstruction	PET/CT: OSEM + TOF + PSF
Image reconstruction	PET/MRI: OSEM
Diseases	Lung carcinoma [n = 14: adenocarcinoma (n = 8), squamous cell carcinoma (n = 5), small cell lung cancer (n = 1)], breast carcinoma [n = 11: scirrhous carcinoma (n = 7), papillotubular carcinoma (n = 1), solid-tubular carcinoma (n = 1), unknown (n = 2)], ovarian carcinoma [n = 5: serous adenocarcinoma (n = 2), serous papillary adenocarcinoma (n = 2), mucinous adenocarcinoma (n = 1)], leukemia [n = 5: FL (n = 3), DLBCL (n = 1), MM (n = 1)], esophageal carcinoma [n = 4: squamous cell carcinoma (n = 3), basaloid carcinoma (n = 1)], uterine tumor [n = 4: carcinosarcoma (n = 2), serous adenocarcinoma (n = 1), endometrioid carcinoma (n = 1)], pancreatic carcinoma [n = 3: adenocarcinoma (n = 2), IPMC (n = 1)], stomach carcinoma [n = 2: adenocarcinoma (n = 1), neuroendocrine carcinoma (n = 1)], rectal carcinoma [n = 2: adenocarcinoma (n = 2)], and other tumors [n = 5: parotid mucoepidermoid carcinoma (n = 1), papillary thyroid cancer (n = 1), thymoma (n = 1), HCC (n = 1), intrahepatic cholangiocarcinoma (n = 1)]

DLBCL, diffuse large B-cell lymphoma; FDG, fluorodeoxyglucose; FL, Follicular lymphoma; MM, multiple myeloma; HCC, hepatocellular carcinoma; IPMC, intraductal papillary mucinous carcinoma; PET, positron emission tomography; CT, computed tomography; MRI, magnetic resonance imaging.